Status:
COMPLETED
A Study to Evaluate Patient Characteristics and Treatment Patterns Among Rheumatoid Arthritis Patients
Lead Sponsor:
Pfizer
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
This is a retrospective cohort study to evaluate patient characteristics, treatment patterns including a 6-factor effectiveness proxy measure, health care resource use and associated costs among Rheum...
Eligibility Criteria
Inclusion
- first pharmacy claim for Tofacitinib and then Etanercept or Adalimumab between Jan 2014 and Sep 2016 represents the index claim
- First, select patients receiving ≥1 Tofacitinib pharmacy claim (Jan 2014-Sep 2016) who did not have a Tofacitinib claim anytime prior to index
- Patients do have \>1 advanced therapy filled on index date
- Physician diagnosis of Rheumatoid Arthritis (in any position) during the 1-year pre-index period, or on the index date
- Age 18+ years at index
Exclusion
- None
Key Trial Info
Start Date :
May 20 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 21 2019
Estimated Enrollment :
1349 Patients enrolled
Trial Details
Trial ID
NCT04047121
Start Date
May 20 2019
End Date
October 21 2019
Last Update
June 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer
Collegeville, Pennsylvania, United States, 19426